LBRX Stock News & Catalysts

FEATURED

LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Strengthened leadership with the appointment of Susan G. Kozauer, M.D., as Chief Medical Officer and Joseph Miller as Chief Financial Officer On track for topline data readout from the pivotal Phase 3 NOVA-2 trial of

Summary

Nov 5, 2026, 4:05 PM ·Globe Newswire

RECENT

LB Pharmaceuticals to Participate in Upcoming Investor Events

NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing

Oct 15, 2026, 4:05 PM ·Globe Newswire

LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress

NEW YORK, Oct. 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing

Oct 10, 2026, 8:00 AM ·Globe Newswire

LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, Oct. 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing

Oct 9, 2026, 4:42 PM ·Globe Newswire

LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing

Oct 6, 2026, 8:00 AM ·Globe Newswire

LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing

Sep 15, 2026, 8:00 AM ·Globe Newswire

LB Pharmaceuticals to Participate in Upcoming September Investor Events

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing

Sep 3, 2026, 4:05 PM ·Globe Newswire

LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing

Sep 3, 2026, 8:00 AM ·Globe Newswire

LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027 Announced plans for pipeline expansion of LB-102 into new neuropsychiatric

Aug 11, 2026, 8:00 AM ·Globe Newswire

LB Pharmaceuticals Announces $150 Million Private Placement

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing

Jul 29, 2026, 8:00 AM ·Globe Newswire

LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia

NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing

Jul 22, 2026, 8:00 AM ·Globe Newswire

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), today announced that it has granted to Christopher Zergebel, the new Senior

Jul 10, 2026, 4:38 PM ·Globe Newswire

LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for

Jun 30, 2026, 8:00 AM ·Globe Newswire

LB Pharmaceuticals to Participate in Upcoming June Investor Events

NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar

May 28, 2026, 4:05 PM ·Globe Newswire

LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression Published results from the Phase 2 NOVA-1 trial of LB-102

May 12, 2026, 4:05 PM ·Globe Newswire

LB Pharmaceuticals Inc Common Stock LBRX · News